A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors M Filipits, M Rudas, R Jakesz, P Dubsky, F Fitzal, CF Singer, O Dietze, ... Clinical Cancer Research 17 (18), 6012-6020, 2011 | 786 | 2011 |
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen W Schroth, MP Goetz, U Hamann, PA Fasching, M Schmidt, S Winter, ... Jama 302 (13), 1429-1436, 2009 | 646 | 2009 |
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes W Schroth, L Antoniadou, P Fritz, M Schwab, T Muerdter, UM Zanger, ... Journal of Clinical Oncology 25 (33), 5187-5193, 2007 | 592 | 2007 |
Molecular resolution of marine turtle stock composition in fishery bycatch: a case study in the Mediterranean L Laurent, P Casale, MN Bradai, BJ Godley, GGAC BRODERICK, ... Molecular Ecology 7 (11), 1529-1542, 1998 | 334 | 1998 |
Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma TE Mürdter, W Schroth, L Bacchus‐Gerybadze, S Winter, G Heinkele, ... Clinical Pharmacology & Therapeutics 89 (5), 708-717, 2011 | 298 | 2011 |
Speciation and phylogeography in the cosmopolitan marine moon jelly, Aurelia sp W Schroth, G Jarms, B Streit, B Schierwater BMC evolutionary biology 2, 1-10, 2002 | 227 | 2002 |
Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer P Saladores, T Mürdter, D Eccles, B Chowbay, NK Zgheib, S Winter, ... The pharmacogenomics journal 15 (1), 84-94, 2015 | 209 | 2015 |
CYP2D6 Genotype and Adjuvant Tamoxifen: Meta‐Analysis of Heterogeneous Study Populations MA Province, MP Goetz, H Brauch, DA Flockhart, JM Hebert, R Whaley, ... Clinical Pharmacology & Therapeutics 95 (2), 216-227, 2014 | 200 | 2014 |
Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters H Brauch, W Schroth, MP Goetz, TE Mürdter, S Winter, JN Ingle, ... Journal of Clinical Oncology 31 (2), 176, 2013 | 138 | 2013 |
CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification W Schroth, U Hamann, PA Fasching, S Dauser, S Winter, M Eichelbaum, ... Clinical Cancer Research 16 (17), 4468-4477, 2010 | 109 | 2010 |
Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment R Hoppe, J Achinger-Kawecka, S Winter, P Fritz, WY Lo, W Schroth, ... European journal of cancer 49 (17), 3598-3608, 2013 | 99 | 2013 |
Automated extraction of DNA and RNA from a single formalin-fixed paraffin-embedded tissue section for analysis of both single-nucleotide polymorphisms and mRNA expression G Hennig, M Gehrmann, U Stropp, H Brauch, P Fritz, M Eichelbaum, ... Clinical chemistry 56 (12), 1845-1853, 2010 | 91 | 2010 |
Evolutionary handicap for turtles W Schroth, B Streit, B Schierwater Nature 384 (6609), 521-522, 1996 | 89 | 1996 |
Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast M Sonnenberg, H van der Kuip, S Haubeiß, P Fritz, W Schroth, G Friedel, ... BMC cancer 8, 1-13, 2008 | 77 | 2008 |
Improved prediction of endoxifen metabolism by CYP2D6 genotype in breast cancer patients treated with tamoxifen W Schroth, S Winter, T Mürdter, E Schaeffeler, D Eccles, B Eccles, ... Frontiers in pharmacology 8, 582, 2017 | 63 | 2017 |
Cancer-Associated Intermediate Conductance Ca2+-Activated K+ Channel KCa3.1 CJ Mohr, FA Steudel, D Gross, P Ruth, WY Lo, R Hoppe, W Schroth, ... Cancers 11 (1), 109, 2019 | 58 | 2019 |
MALDI‐TOF MS and TaqMan® assisted SNP genotyping of DNA isolated from formalin‐fixed and paraffin‐embedded tissues (FFPET) M Jaremko, C Justenhoven, BK Abraham, W Schroth, P Fritz, S Brod, ... Human mutation 25 (3), 232-238, 2005 | 55 | 2005 |
Estrogen‐mediated downregulation of CD24 in breast cancer cells BA Kaipparettu, S Malik, SD Konduri, W Liu, M Rokavec, H van der Kuip, ... International journal of cancer 123 (1), 66-72, 2008 | 49 | 2008 |
Genetic polymorphism of cytochrome P450 2D6 determines oestrogen receptor activity of the major infertility drug clomiphene via its active metabolites TE Mürdter, R Kerb, M Turpeinen, W Schroth, B Ganchev, GM Böhmer, ... Human molecular genetics 21 (5), 1145-1154, 2012 | 45 | 2012 |
SK4 channels modulate Ca2+ signalling and cell cycle progression in murine breast cancer FA Steudel, CJ Mohr, B Stegen, HY Nguyen, A Barnert, M Steinle, ... Molecular Oncology 11 (9), 1172-1188, 2017 | 42 | 2017 |